|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:bortezomib
|
|
gptkbp:activities
|
proteasome inhibitor
|
|
gptkbp:approves
|
gptkb:2003
gptkb:FDA
|
|
gptkbp:can_be_used_with
|
gptkb:lenalidomide
gptkb:thalidomide
gptkb:dexamethasone
|
|
gptkbp:class
|
antineoplastic agent
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
newly diagnosed multiple myeloma
relapsed multiple myeloma
relapsed mantle cell lymphoma
|
|
gptkbp:discontinued
|
not applicable
|
|
gptkbp:form
|
lyophilized powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Velcade
|
|
gptkbp:ingredients
|
gptkb:bortezomib
C19 H25 B N4 O4
|
|
gptkbp:invention
|
gptkb:2023
|
|
gptkbp:is_atype_of
|
L01 X X32
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
mantle cell lymphoma
|
|
gptkbp:manager
|
intravenous
subcutaneous
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:provides_information_on
|
ASCO guidelines
NCCN guidelines
|
|
gptkbp:related_to
|
cancer therapy
hematologic malignancies
proteasome
|
|
gptkbp:research_focus
|
biomarker identification
combination therapies
resistance mechanisms
new formulations
pediatric applications
|
|
gptkbp:side_effect
|
fatigue
nausea
neurological effects
peripheral neuropathy
thrombocytopenia
infection risk
cardiac toxicity
gastrointestinal toxicity
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of
|
179324-69-7
|